Kenneth D. Steinsapir receives rare USPTO patent for Microdroplet BOTOX
Kenneth D. Steinsapir, M.D., has been issued a rare patent (US 7,846,457 B2) by The United States Patent and Trademark Office for the invention of a breakthrough method for administering cosmetic botulinum toxin. The patent for Microdroplet botulinum toxin, a nonsurgical cosmetic facial treatment that improves upon standard BOTOX treatments, was officially approved on December 7, 2010.